• 1
    Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications . Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organisation, 1999.
  • 2
    Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 248697.DOI: 10.1001/jama.285.19.2486
  • 3
    Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 270916.DOI: 10.1001/jama.288.21.2709
  • 4
    Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 6839.
  • 5
    Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595607.
  • 6
    Pinkney JH, Stehouwer CDA, Coppack SW, Yudkin JS. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 1997; 46: s9s13.
  • 7
    Meigs JB, Wilson PW, Nathan DM, D'Agostino RB Sr, Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 2003; 52: 21607.
  • 8
    Mansfield MW, Grant PJ. Fibrinolysis and diabetic retinopathy in NIDDM. Diabetes Care 1995; 18: 157781.
  • 9
    El Khawand C, Jamart J, Donckier J, Chatelain B, Lavenne E, Moriau M, Buysschaert M. Hemostasis variables in type I diabetic patients without demonstrable vascular complications. Diabetes Care 1993; 16: 113745.
  • 10
    Blann AD, Lip GY. Endothelial integrity, soluble adhesion molecules and platelet markers in type 1 diabetes mellitus. Diabet Med 1998; 15: 63442.
  • 11
    Carter AM, Grant PJ. Vascular homeostasis, adhesion molecules, and macrovascular disease in non-insulin-dependent diabetes mellitus. Diabet Med 1997; 14: 42332.
  • 12
    Lim HS, Lip GY, Blann AD. Plasma von Willebrand factor and the development of the metabolic syndrome in patients with hypertension. J Clin Endocrinol Metab 2004; 89: 537781.DOI: 10.1210/jc.2004-0616
  • 13
    Duncan BB, Schmidt MI, Chambless LE, Folsom AR, Carpenter M, Heiss G. Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults—the ARIC study. Atherosclerosis Risk in Communities. Obes Res 2000; 8: 27986.
  • 14
    Agewall S, Bokemark L, Wikstrand J, Lindahl A, Fagerberg B. Insulin sensitivity and hemostatic factors in clinically healthy 58-year-old men. Thromb Haemost 2000; 84: 5715.
  • 15
    Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004; 28: 135764.DOI: 10.1038/sj.ijo.0802778
  • 16
    Tamminen M, Lassila R, Westerbacka J, Vehkavaara S, Yki-Jarvinen H. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in non-diabetic subjects. Int J Obes Relat Metab Disord 2003; 27: 90711.DOI: 10.1038/sj.ijo.0802312
  • 17
    Bowles LK, Cooper JA, Howarth DJ, Miller GJ, MacCallum PK. Associations of haemostatic variables with body mass index: a community-based study. Blood Coagul Fibrinolysis 2003; 14: 56973.
  • 18
    Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1: 15759.DOI: 10.1046/j.1538-7836.2003.00279.x
  • 19
    Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, Vuksan V, Teo K, Davis B, Montague P, Yusuf S. Study of Health Assessment and Risk Evaluation in Aboriginal Peoples Investigators. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003; 108: 4205.
  • 20
    De Gaetano G. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357: 8995.DOI: 10.1016/S0140-6736(00)03539-X
  • 21
    Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004; 292: 14406.DOI: 10.1001/jama.292.12.1440
  • 22
    Ferri C, Desideri G, Valenti M, Bellini C, Pasin M, Santucci A, De Mattia G. Early upregulation of endothelial adhesion molecules in obese hypertensive men. Hypertension 1999; 34: 56873.
  • 23
    Thompson SG, Kienast J, Pyke SDM, Haverkate F, Van De Loo J for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 63541.DOI: 10.1056/NEJM199503093321003
  • 24
    Jager A, Van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects—The Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19: 30718.
  • 25
    Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, Wu KK. Associations of factor VIII and von Willebrand factor with age, race, sex and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993; 70: 3805.
  • 26
    Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Juhan-Vague I, PRIME Study Group. Endothelial cell markers and the risk of coronary heart disease. The Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study. Circulation 2004; 109: 13438.